Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 17/20 | 0.43 |
| ▸ | IL6 | P05231 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487355 | 0.90 | SMN1; SMN2 (0.44) | CYP3A4P2RX3IL6TLR7SOS1 | |
| SCHEMBL17488010 | 0.87 | CYP3A4 (0.45) | CYP3A4P2RX3IL6TLR7 | |
| SCHEMBL17488297 | 0.87 | CYP3A4 (0.46) | CYP3A4P2RX3IL6TLR7 | |
| SCHEMBL17487358 | 0.83 | SOS1 (0.48) | CYP3A4P2RX3SOS1 | |
| SCHEMBL17488305 | 0.83 | LMNA (0.47) | CYP3A4P2RX3 | |
| SCHEMBL17487435 | 0.83 | P2RX3 (0.43) | CYP3A4P2RX3 | |
| SCHEMBL17488112 | 0.82 | CYP3A4 (0.48) | CYP3A4P2RX3IL6TLR7 | |
| SCHEMBL17487737 | 0.81 | CYP3A4 (0.44) | CYP3A4P2RX3 | |
| SCHEMBL17488172 | 0.81 | CYP3A4 (0.54) | CYP3A4P2RX3 | |
| SCHEMBL18960415 | 0.80 | CYP3A4 (0.46) | CYP3A4P2RX3IL6TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | CYP3A4 261/4885P2RX3 750/4885IL6 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.